Company intelligence / Profile preview

ARYA Sciences Holdings IV

Ownership: Private
Development stage: Other

Overview

Adagio Medical obtained CE Mark approval and launched the vCLAS catheter in Europe in Q2 2024. The company received FDA approval for the FULCRUM-VT Pivotal IDE study with patient enrollment expected to begin in September 2024. The company raised approximately $84.2 million through the SPAC merger.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Perceptive AdvisorsRA Capital ManagementRTW Investments

Beyond the preview

Go deeper on ARYA Sciences Holdings IV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARYA Sciences Holdings IV.

Explore the full profile